The overexpression and/or activation of FAK has been detected in numerous cancers, such as breast cancers, hepatocellular carcinoma, head and neck cancer, ovarian cancer and lung cancer (Mohanty et al., 2020). This evidence concerns the gene PTK2 and ovarian cancer.